<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01848054</url>
  </required_header>
  <id_info>
    <org_study_id>OX219-007</org_study_id>
    <nct_id>NCT01848054</nct_id>
  </id_info>
  <brief_title>Study to Assess Efficacy and Safety of BNX Sublingual Tablets for the Induction of Treatment of Opioid Dependence</brief_title>
  <official_title>A Randomized, Blinded, Active-controlled Non-inferiority Study of the Efficacy and Safety of OX219 for the Induction of Treatment of Opioid Dependence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Orexo AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Worldwide Clinical Trials</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Orexo AB</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study was to assess the efficacy of induction treatment with
      buprenorphine/naloxone (BNX) sublingual tablet s compared with induction treatment with
      buprenorphine only. The hypothesis is that starting directly on OX219 works equally well
      (e.g. not significantly worse) as starting on buprenorphine only and switching to OX219 on
      Day 3.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This was a prospective, randomized, multicenter, blinded, parallel-group, active-controlled,
      non-inferiority study conducted at 13 sites within the US. Eligible patients participated in
      8 treatment visits on Days 1, 2, 3, 4, 8, 15, 22, and 29. Effectiveness of treatment was
      assessed as follows:

        -  Retention in treatment at Day 3

        -  Clinician and patient assessments of opioid withdrawal symptoms

        -  Assessment opioid cravings
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Retention in Treatment in the Per Protocol Population</measure>
    <time_frame>Day 3</time_frame>
    <description>Retention in treatment at Day 3 in the per protocol population (n=256) was defined as the number of patients in each induction arm completing the induction phase and who received study medication on Day 3. Treatment with BNX sublingual tablets was considered non-inferior to generic buprenorphine if the lower limit of the 95% confidence interval for the difference between BNX and generic buprenorphine was ≥-10% in the number of patients retained in treatment on Day 3.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve (AUC) in Clinical Opiate Withdrawal Scale (COWS) Total Score on Days 1 to 3 Inclusive</measure>
    <time_frame>Pre-dose on Days 1-3 and 0.5, 1, 1.5, 3, and 6 hours post-dose on Day 1</time_frame>
    <description>Least squares mean AUC in COWS total score on Days 1 to 3; COWS scores range from 0-48, with a lower score being more favorable</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC in Subjective Opiate Withdrawal Scale (SOWS) Total Score on Days 1 to 3 Inclusive</measure>
    <time_frame>Pre-dose on Days 1-3 and 0.5, 1, 1.5, 3, and 6 hours post-dose on Day 1</time_frame>
    <description>Least squares mean AUC day 1 pre-dose through Day 3 in SOWS; SOWS scores range from 0-64, with a lower score being more favorable</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC in Visual Analog Scale (VAS) Score for Craving on Days 1 to 3 Inclusive</measure>
    <time_frame>Pre-dose on Days 1-3 and 0.5, 1, 1.5, 3, and 6 hours post-dose on Day 1</time_frame>
    <description>Least squares mean AUC measurement in VAS score for cravings on Days 1 to 3; the VAS craving scores range from 0 (&quot;no cravings&quot;) to 100 (&quot;most intense craving I have ever had&quot;)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in COWS Total Score After Day 3 (Maintenance Phase)</measure>
    <time_frame>Predose on Days 4, 8, 15, 22, and 29</time_frame>
    <description>Mean change from baseline in COWS total scores during the maintenance phase (Days 4, 8, 15, 22, and 29); COWS scores range from 0-48, with a lower score being more favorable</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in SOWS Total Score After Day 3 (Maintenance Phase)</measure>
    <time_frame>Pre-dose on Days 4, 8, 15, 22, and 29</time_frame>
    <description>Mean change from baseline in SOWS total scores during the maintenance phase (Days 4, 8, 15, 22, and 29); SOWS scores range from 0-64, with a lower score being more favorable</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in the VAS Score for Cravings After Day 3 (Maintenance Phase)</measure>
    <time_frame>Pre-dose on Days 4, 8, 15, 22, and 29</time_frame>
    <description>Mean change from baseline in VAS scores for cravings during the maintenance phase (Days 4, 8, 15, 22, and 29); the VAS craving scores range from 0 (&quot;no cravings&quot;) to 100 (&quot;most intense craving I have ever had&quot;)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Retention in Treatment in the Full Analysis Population</measure>
    <time_frame>Day 3</time_frame>
    <description>Retention in treatment at Day 3 in the full analysis population (N=310) was defined as the number of patients in each induction arm completing the induction phase and who received study medication on Day 3. Treatment with BNX sublingual tablets was considered non-inferior to generic buprenorphine if the lower limit of the 95% confidence interval for the difference between BNX and generic buprenorphine was ≥-10% in the number of patients retained in treatment on Day 3.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">313</enrollment>
  <condition>Opioid-Related Disorders</condition>
  <condition>Opiate Dependence</condition>
  <arm_group>
    <arm_group_label>BNX Sublingual Tablets Induction</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Day 1-2 (Blinded Induction): BNX sublingual tablets
Day 3-28 (Open-label Maintenance): BNX sublingual tablets</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Buprenorphine Induction</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Day 1-2 (Blinded Induction): Generic buprenorphine sublingual tablets
Day 3-28 (Open-label Maintenance): BNX sublingual tablets</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Buprenorphine/naloxone sublingual tablets</intervention_name>
    <description>Advanced-formulation buprenorphine/naloxone sublingual tablets</description>
    <arm_group_label>BNX Sublingual Tablets Induction</arm_group_label>
    <arm_group_label>Buprenorphine Induction</arm_group_label>
    <other_name>Zubsolv</other_name>
    <other_name>OX219</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Buprenorphine</intervention_name>
    <description>Buprenorphine sublingual tablets</description>
    <arm_group_label>Buprenorphine Induction</arm_group_label>
    <other_name>Generic buprenorphine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Able to read, comprehend, and sign the informed consent form and willingly provide
             written informed consent

          -  Prepared to engage in opioid replacement therapy and to abstain from opioid
             utilization other than the study drug, and from other illicit drugs

          -  Male or female, 18 to 65 years of age (inclusive)

          -  Met clinical criteria for opioid dependence in past 12 months based on DSM-IV-TR

          -  Provided buprenorphine-negative urine drug screen prior to randomization

          -  Provided negative urine pregnancy test

          -  Females of childbearing potential were required to be using a reliable method of
             contraception (e.g., hormonal, condom with spermicide, intrauterine device [IUD])
             after the screening visit and for the duration of the study

          -  Participants receiving opioids for pain must receive clearance from their prescribing
             physician to be withdrawn from their prescribed opioids

          -  Generally good health as determined by the investigator

          -  Participants should demonstrate at least mild withdrawal symptoms (defined as a COWS
             score &gt;9 at Day 1 predose)

        Exclusion Criteria:

          -  Females who are pregnant or lactating, or planning to be pregnant during study

          -  Any previous prescribed treatment with buprenorphine monotherapy (e.g., generic
             buprenorphine sublingual tablets)

          -  Prescribed treatment with buprenorphine or naloxone within 90 days prior to start of
             treatment

          -  Methadone patients with any daily dose over 30 mg during the past week and who
             received the last dose of methadone less than 30 hours prior to start of treatment

          -  Participants who are unwilling or unable to comply with the requirements of the
             protocol

          -  Participants who are participating in any other clinical study in which medication(s)
             are being delivered or who have used an investigational drug or device within the last
             30 days

          -  Participants with any known allergy or sensitivity or intolerance to buprenorphine,
             naloxone, or any related drug

          -  Participants who are on the staff, affiliated with, or a family member of the staff
             personnel directly involved with this study

          -  Participants with serious untreated Axis I DSM-IV-TR psychiatric comorbidity

          -  Tongue piercing or other piercings in the mouth, including lips and cheek

          -  Participants with current or history of clinically significant medical disorder or
             condition

          -  Participants who are human immunodeficiency virus (HIV)-seropositive with a CD4+ count
             &lt;200 or active acquired immune deficiency syndrome (AIDS)

          -  Participants who have any Class III or IV congestive heart failure, symptomatic
             myocardial ischemia, a history of long QT syndrome.

          -  Participants who are currently taking Class 1A antiarrhythmic medications or Class III
             antiarrhythmic medications

          -  Participants who have uncontrolled hypertension or clinically significant ECG
             abnormalities

          -  Participants who have a pulse oximetry ≤93% at screening, due to any medical reason.

          -  Individuals with AST or ALT levels ≥3 X the upper limit of normal or total bilirubin
             or creatinine ≥1.5 X ULN, on the screening laboratory assessments

          -  Participants with known significant liver disease.

          -  Participants who take any medication, nutraceutical, herbal product with known CYP3A4
             inhibition or induction properties within 14 days of screening.

          -  Participants who are at suicidal risk
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lynn Webster</last_name>
    <role>Principal Investigator</role>
    <affiliation>Life Tree Pain Clinic, 3838 S 700 E Suite 200, Salt Lake City, UT 84106</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Haleyville</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>National City</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oceanside</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Maitland</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>North Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fall River</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Flowood</city>
        <state>Mississippi</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 2, 2013</study_first_submitted>
  <study_first_submitted_qc>May 2, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 7, 2013</study_first_posted>
  <results_first_submitted>April 10, 2015</results_first_submitted>
  <results_first_submitted_qc>June 22, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 24, 2015</results_first_posted>
  <last_update_submitted>April 3, 2017</last_update_submitted>
  <last_update_submitted_qc>April 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>opioid dependence, buprenorphine/naloxone, sublingual</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Opioid-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Analgesics, Opioid</mesh_term>
    <mesh_term>Buprenorphine</mesh_term>
    <mesh_term>Buprenorphine, Naloxone Drug Combination</mesh_term>
    <mesh_term>Naloxone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>A total of 313 patients were enrolled. Three patients who were randomized did not receive study drug, making the participant flow 310.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>BNX Sublingual Tablets Induction</title>
          <description>Days 1-2: Induction on BNX sublingual tablets (blinded); Days 3-28: Maintenance treatment with BNX sublingual tablets (open-label)</description>
        </group>
        <group group_id="P2">
          <title>Buprenorphine Induction</title>
          <description>Days 1-2: Induction on buprenorphine sublingual tablets (blinded); Days 3-28: Maintenance treatment with BNX sublingual tablets (open-label)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Induction Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="155"/>
                <participants group_id="P2" count="155"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="132"/>
                <participants group_id="P2" count="147"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Stabilization/Maintenance</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="132"/>
                <participants group_id="P2" count="147"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="92"/>
                <participants group_id="P2" count="107"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="40"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>BNX Sublingual Tablets Induction</title>
          <description>Days 1-2: Induction on BNX sublingual tablets (blinded); Days 3-28: Maintenance treatment with BNX sublingual tablets (open-label)</description>
        </group>
        <group group_id="B2">
          <title>Buprenorphine Induction</title>
          <description>Days 1-2: Induction on buprenorphine sublingual tablets (blinded); Days 3-28: Maintenance treatment with BNX sublingual tablets (open-label)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="155"/>
            <count group_id="B2" value="155"/>
            <count group_id="B3" value="310"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38.9" spread="10.6"/>
                    <measurement group_id="B2" value="38.0" spread="10.9"/>
                    <measurement group_id="B3" value="38.4" spread="10.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                    <measurement group_id="B2" value="52"/>
                    <measurement group_id="B3" value="107"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="100"/>
                    <measurement group_id="B2" value="103"/>
                    <measurement group_id="B3" value="203"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="38"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="134"/>
                    <measurement group_id="B2" value="135"/>
                    <measurement group_id="B3" value="269"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body mass index (BMI)</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.2" spread="6.7"/>
                    <measurement group_id="B2" value="25.3" spread="5.0"/>
                    <measurement group_id="B3" value="25.7" spread="5.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Duration of opioid dependence</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13.3" spread="9.3"/>
                    <measurement group_id="B2" value="11.6" spread="9.2"/>
                    <measurement group_id="B3" value="12.4" spread="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Retention in Treatment in the Per Protocol Population</title>
        <description>Retention in treatment at Day 3 in the per protocol population (n=256) was defined as the number of patients in each induction arm completing the induction phase and who received study medication on Day 3. Treatment with BNX sublingual tablets was considered non-inferior to generic buprenorphine if the lower limit of the 95% confidence interval for the difference between BNX and generic buprenorphine was ≥–10% in the number of patients retained in treatment on Day 3.</description>
        <time_frame>Day 3</time_frame>
        <population>Per protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>BNX Sublingual Tablets Induction</title>
            <description>Days 1-2: Induction on BNX sublingual tablets (blinded); Days 3-28: Maintenance treatment with BNX sublingual tablets (open-label)</description>
          </group>
          <group group_id="O2">
            <title>Buprenorphine Induction</title>
            <description>Days 1-2: Induction on buprenorphine sublingual tablets (blinded); Days 3-28: Maintenance treatment with BNX sublingual tablets (open-label)</description>
          </group>
        </group_list>
        <measure>
          <title>Retention in Treatment in the Per Protocol Population</title>
          <description>Retention in treatment at Day 3 in the per protocol population (n=256) was defined as the number of patients in each induction arm completing the induction phase and who received study medication on Day 3. Treatment with BNX sublingual tablets was considered non-inferior to generic buprenorphine if the lower limit of the 95% confidence interval for the difference between BNX and generic buprenorphine was ≥–10% in the number of patients retained in treatment on Day 3.</description>
          <population>Per protocol population</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="128"/>
                <count group_id="O2" value="128"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="113"/>
                    <measurement group_id="O2" value="122"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The primary efficacy analysis of retention in treatment at Day 3 was assessed in the per protocol population. In addition, a sensitivity analysis assessed retention in treatment in the full analysis population. For these assessments, the margin to determine non-inferiority (i.e., lower limit of the 95% CI for the difference between BNX and generic buprenorphine of ≥–10%) was selected based on clinical experience to justify comparison between the 2 treatments.</non_inferiority_desc>
            <p_value>&lt;0.05</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>Comparisons between treatment groups were reported with 2-sided p values using 95% CIs for the difference.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Curve (AUC) in Clinical Opiate Withdrawal Scale (COWS) Total Score on Days 1 to 3 Inclusive</title>
        <description>Least squares mean AUC in COWS total score on Days 1 to 3; COWS scores range from 0-48, with a lower score being more favorable</description>
        <time_frame>Pre-dose on Days 1-3 and 0.5, 1, 1.5, 3, and 6 hours post-dose on Day 1</time_frame>
        <population>Full analysis population</population>
        <group_list>
          <group group_id="O1">
            <title>BNX Sublingual Tablets Induction</title>
            <description>Days 1-2: Induction on BNX sublingual tablets (blinded); Days 3-28: Maintenance treatment with BNX sublingual tablets (open-label)</description>
          </group>
          <group group_id="O2">
            <title>Buprenorphine Induction</title>
            <description>Days 1-2: Induction on buprenorphine sublingual tablets (blinded); Days 3-28: Maintenance treatment with BNX sublingual tablets (open-label)</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve (AUC) in Clinical Opiate Withdrawal Scale (COWS) Total Score on Days 1 to 3 Inclusive</title>
          <description>Least squares mean AUC in COWS total score on Days 1 to 3; COWS scores range from 0-48, with a lower score being more favorable</description>
          <population>Full analysis population</population>
          <units>score x hour</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="154"/>
                <count group_id="O2" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.21" spread="4.3"/>
                    <measurement group_id="O2" value="6.88" spread="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC in Subjective Opiate Withdrawal Scale (SOWS) Total Score on Days 1 to 3 Inclusive</title>
        <description>Least squares mean AUC day 1 pre-dose through Day 3 in SOWS; SOWS scores range from 0-64, with a lower score being more favorable</description>
        <time_frame>Pre-dose on Days 1-3 and 0.5, 1, 1.5, 3, and 6 hours post-dose on Day 1</time_frame>
        <population>Full analysis population; patients with missing data were excluded from the analysis and are reflected in the number of participants analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>BNX Sublingual Tablets Induction</title>
            <description>Days 1-2: Induction on BNX sublingual tablets (blinded); Days 3-28: Maintenance treatment with BNX sublingual tablets (open-label)</description>
          </group>
          <group group_id="O2">
            <title>Buprenorphine Induction</title>
            <description>Days 1-2: Induction on buprenorphine sublingual tablets (blinded); Days 3-28: Maintenance treatment with BNX sublingual tablets (open-label)</description>
          </group>
        </group_list>
        <measure>
          <title>AUC in Subjective Opiate Withdrawal Scale (SOWS) Total Score on Days 1 to 3 Inclusive</title>
          <description>Least squares mean AUC day 1 pre-dose through Day 3 in SOWS; SOWS scores range from 0-64, with a lower score being more favorable</description>
          <population>Full analysis population; patients with missing data were excluded from the analysis and are reflected in the number of participants analyzed</population>
          <units>score x hour</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
                <count group_id="O2" value="153"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.7" spread="13.5"/>
                    <measurement group_id="O2" value="17.4" spread="12.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC in Visual Analog Scale (VAS) Score for Craving on Days 1 to 3 Inclusive</title>
        <description>Least squares mean AUC measurement in VAS score for cravings on Days 1 to 3; the VAS craving scores range from 0 (&quot;no cravings&quot;) to 100 (&quot;most intense craving I have ever had&quot;)</description>
        <time_frame>Pre-dose on Days 1-3 and 0.5, 1, 1.5, 3, and 6 hours post-dose on Day 1</time_frame>
        <population>Full analysis population; patients with missing data were excluded from the analysis and are reflected in the number of participants analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>BNX Sublingual Tablets Induction</title>
            <description>Days 1-2: Induction on BNX sublingual tablets (blinded); Days 3-28: Maintenance treatment with BNX sublingual tablets (open-label)</description>
          </group>
          <group group_id="O2">
            <title>Buprenorphine Induction</title>
            <description>Days 1-2: Induction on buprenorphine sublingual tablets (blinded); Days 3-28: Maintenance treatment with OX219 buprenorphine/naloxone sublingual tablets (open-label)
OX219 buprenorphine/naloxone: OX219 buprenorphine/naloxone sublingual tablets
Buprenorphine: Buprenorphine sublingual tablets</description>
          </group>
        </group_list>
        <measure>
          <title>AUC in Visual Analog Scale (VAS) Score for Craving on Days 1 to 3 Inclusive</title>
          <description>Least squares mean AUC measurement in VAS score for cravings on Days 1 to 3; the VAS craving scores range from 0 (&quot;no cravings&quot;) to 100 (&quot;most intense craving I have ever had&quot;)</description>
          <population>Full analysis population; patients with missing data were excluded from the analysis and are reflected in the number of participants analyzed</population>
          <units>score x hour</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="153"/>
                <count group_id="O2" value="155"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.0" spread="25.3"/>
                    <measurement group_id="O2" value="39.5" spread="24.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in COWS Total Score After Day 3 (Maintenance Phase)</title>
        <description>Mean change from baseline in COWS total scores during the maintenance phase (Days 4, 8, 15, 22, and 29); COWS scores range from 0-48, with a lower score being more favorable</description>
        <time_frame>Predose on Days 4, 8, 15, 22, and 29</time_frame>
        <population>Full analysis population; patients with missing data were excluded from the analysis</population>
        <group_list>
          <group group_id="O1">
            <title>BNX Sublingual Tablets Induction</title>
            <description>Days 1-2: Induction on BNX sublingual tablets (blinded); Day 3-28: Maintenance treatment with BNX sublingual tablets (open-label)</description>
          </group>
          <group group_id="O2">
            <title>Buprenorphine Induction</title>
            <description>Days 1-2: Induction on buprenorphine sublingual tablets (blinded); Days 3-28: Maintenance treatment with BNX sublingual tablets (open-label)</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in COWS Total Score After Day 3 (Maintenance Phase)</title>
          <description>Mean change from baseline in COWS total scores during the maintenance phase (Days 4, 8, 15, 22, and 29); COWS scores range from 0-48, with a lower score being more favorable</description>
          <population>Full analysis population; patients with missing data were excluded from the analysis</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="155"/>
                <count group_id="O2" value="155"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.4" spread="5.8"/>
                    <measurement group_id="O2" value="-8.5" spread="5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.2" spread="4.9"/>
                    <measurement group_id="O2" value="-10.1" spread="5.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.9" spread="4.9"/>
                    <measurement group_id="O2" value="-11.1" spread="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.5" spread="4.7"/>
                    <measurement group_id="O2" value="-11.6" spread="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29/premature discontinuation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.5" spread="5.2"/>
                    <measurement group_id="O2" value="-11.4" spread="5.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in SOWS Total Score After Day 3 (Maintenance Phase)</title>
        <description>Mean change from baseline in SOWS total scores during the maintenance phase (Days 4, 8, 15, 22, and 29); SOWS scores range from 0-64, with a lower score being more favorable</description>
        <time_frame>Pre-dose on Days 4, 8, 15, 22, and 29</time_frame>
        <population>Full analysis population; patients with missing data were excluded from the analysis</population>
        <group_list>
          <group group_id="O1">
            <title>BNX Induction</title>
            <description>Days 1-2: Induction on BNX sublingual tablets (blinded); Days 3-28: Maintenance treatment with BNX sublingual tablets (open-label)</description>
          </group>
          <group group_id="O2">
            <title>Buprenorphine Induction</title>
            <description>Days 1-2: Induction on buprenorphine sublingual tablets (blinded); Days 3-28: Maintenance treatment with BNX sublingual tablets (open-label)</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in SOWS Total Score After Day 3 (Maintenance Phase)</title>
          <description>Mean change from baseline in SOWS total scores during the maintenance phase (Days 4, 8, 15, 22, and 29); SOWS scores range from 0-64, with a lower score being more favorable</description>
          <population>Full analysis population; patients with missing data were excluded from the analysis</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="155"/>
                <count group_id="O2" value="155"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-24.7" spread="16.0"/>
                    <measurement group_id="O2" value="-18.9" spread="13.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-27.0" spread="15.8"/>
                    <measurement group_id="O2" value="-21.3" spread="13.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-29.2" spread="15.5"/>
                    <measurement group_id="O2" value="-23.3" spread="13.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-30.8" spread="15.6"/>
                    <measurement group_id="O2" value="-24.1" spread="13.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29/premature discontinuation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-30.4" spread="16.0"/>
                    <measurement group_id="O2" value="-24.3" spread="14.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in the VAS Score for Cravings After Day 3 (Maintenance Phase)</title>
        <description>Mean change from baseline in VAS scores for cravings during the maintenance phase (Days 4, 8, 15, 22, and 29); the VAS craving scores range from 0 (&quot;no cravings&quot;) to 100 (&quot;most intense craving I have ever had&quot;)</description>
        <time_frame>Pre-dose on Days 4, 8, 15, 22, and 29</time_frame>
        <population>Full analysis population; patients with missing data were excluded from the analysis</population>
        <group_list>
          <group group_id="O1">
            <title>BNX Sublingual Tablets Induction</title>
            <description>Days 1-2: Induction on BNX sublingual tablets (blinded); Days 3-28: Maintenance treatment with BNX sublingual tablets (open-label)</description>
          </group>
          <group group_id="O2">
            <title>Buprenorphine Induction</title>
            <description>Days 1-2: Induction on buprenorphine sublingual tablets (blinded); Days 3-28: Maintenance treatment with BNX sublingual tablets (open-label)</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in the VAS Score for Cravings After Day 3 (Maintenance Phase)</title>
          <description>Mean change from baseline in VAS scores for cravings during the maintenance phase (Days 4, 8, 15, 22, and 29); the VAS craving scores range from 0 (&quot;no cravings&quot;) to 100 (&quot;most intense craving I have ever had&quot;)</description>
          <population>Full analysis population; patients with missing data were excluded from the analysis</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="155"/>
                <count group_id="O2" value="155"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-40.1" spread="28.6"/>
                    <measurement group_id="O2" value="-34.2" spread="29.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-46.1" spread="29.5"/>
                    <measurement group_id="O2" value="-39.9" spread="27.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-48.5" spread="30.3"/>
                    <measurement group_id="O2" value="-44.3" spread="26.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-53.3" spread="29.5"/>
                    <measurement group_id="O2" value="-47.2" spread="25.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-52.7" spread="29.1"/>
                    <measurement group_id="O2" value="-45.1" spread="29.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Retention in Treatment in the Full Analysis Population</title>
        <description>Retention in treatment at Day 3 in the full analysis population (N=310) was defined as the number of patients in each induction arm completing the induction phase and who received study medication on Day 3. Treatment with BNX sublingual tablets was considered non-inferior to generic buprenorphine if the lower limit of the 95% confidence interval for the difference between BNX and generic buprenorphine was ≥–10% in the number of patients retained in treatment on Day 3.</description>
        <time_frame>Day 3</time_frame>
        <population>Full analysis population; patients with missing data were excluded from the analysis</population>
        <group_list>
          <group group_id="O1">
            <title>BNX Sublingual Tablets Induction</title>
            <description>Days 1-2: Induction on BNX sublingual tablets (blinded); Days 3-28: Maintenance treatment with BNX sublingual tablets (open-label)</description>
          </group>
          <group group_id="O2">
            <title>Buprenorphine Induction</title>
            <description>Days 1-2: Induction on buprenorphine sublingual tablets (blinded); Days 3-28: Maintenance treatment with OX219 buprenorphine/naloxone sublingual tablets (open-label)</description>
          </group>
        </group_list>
        <measure>
          <title>Retention in Treatment in the Full Analysis Population</title>
          <description>Retention in treatment at Day 3 in the full analysis population (N=310) was defined as the number of patients in each induction arm completing the induction phase and who received study medication on Day 3. Treatment with BNX sublingual tablets was considered non-inferior to generic buprenorphine if the lower limit of the 95% confidence interval for the difference between BNX and generic buprenorphine was ≥–10% in the number of patients retained in treatment on Day 3.</description>
          <population>Full analysis population; patients with missing data were excluded from the analysis</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="155"/>
                <count group_id="O2" value="155"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="132"/>
                    <measurement group_id="O2" value="147"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The primary efficacy analysis of retention in treatment at Day 3 was assessed in the per protocol population. In addition, a sensitivity analysis assessed retention in treatment in the full analysis population. For these assessments, the margin to determine non-inferiority (i.e., lower limit of the 95% CI for the difference between BNX and generic buprenorphine of ≥–10%) was selected based on clinical experience to justify comparison between the 2 treatments.</non_inferiority_desc>
            <p_value>&lt;0.05</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>Comparisons between treatment groups were reported with 2-sided p values using 95% CIs for the difference.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Blinded Induction Phase (Days 1-2) and Open Label Maintenance Phase (Days 3-28)</time_frame>
      <desc>The safety population included 310 patients.</desc>
      <group_list>
        <group group_id="E1">
          <title>BNX Sublingual Tablets Induction</title>
          <description>Days 1-2: Induction on BNX sublingual tablets (blinded); Days 3-28: Maintenance treatment with BNX sublingual tablets (open-label)</description>
        </group>
        <group group_id="E2">
          <title>Buprenorphine Induction</title>
          <description>Days 1-2: Induction on buprenorphine sublingual tablets (blinded); Days 3-28: Maintenance treatment with BNX sublingual tablets (open-label)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (16.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <description>Considered unrelated to study treatment; reported during the blinded induction phase</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bacteremia secondary to pyelonephritis</sub_title>
                <description>Considered unrelated to study treatment; reported during the open-label maintenance phase</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Attempted suicide</sub_title>
                <description>Considered unrelated to study treatment; reported during the open-label maintenance phase</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (16.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="155"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea (Induction)</sub_title>
                <description>Adverse events reported during the blinded induction phase</description>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="155"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Vomiting (Induction)</sub_title>
                <description>Adverse events reported during the blinded induction phase</description>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="155"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache (Induction)</sub_title>
                <description>Adverse events reported during the blinded induction phase</description>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="155"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia (Induction)</sub_title>
                <description>Adverse events reported during the blinded induction phase</description>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="155"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Lynn R. Webster, MD</name_or_title>
      <organization>PRA International</organization>
      <phone>801-892-5140</phone>
      <email>LRWebsterMD@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

